CryoLife, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.CryoLife, Inc. incorporated in 1984 in Florida, was the first biomedical company to specialize in the ultra-low temperature preservation of human heart valves used for cardiac reconstruction, primarily in children born with heart defects. The Company preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular transplant applications. The human tissues distributed by CryoLife include the CryoValve® SG pulmonary human heart valve and the CryoPatch® SG pulmonary cardiac patch tissue, both processed using CryoLife’s proprietary SynerGraft® technology. CryoLife’s medical devices consist primarily of surgical adhesives, sealants, and hemostats including BioGlue® Surgical Adhesive, BioFoam® Surgical Matrix, PerClot®, which the Company began distributing for Starch Medical, Inc. in October 2010.The Company preserves small diameter human saphenous vein conduits for use in peripheral vascular reconstructions and coronary bypass surgery. Failure to achieve revascularization of an obstructed vessel may result in the loss of a limb or even death of the patient. When patients require bypass surgery, the surgeon’s first choicegenerally is the patient’s own vein tissue. However, in cases of advanced vascular disease, 30% of patients have unsuitable vein tissue for transplantation, and the surgeon must consider using synthetic grafts or preserved human vascular tissue. Small diameter synthetic vascular grafts are generally not optimal for below-the-knee surgeries because they have a tendency to obstruct over time. Preserved human vascular tissues tend to remain open longer and as such are used in indications where synthetics typically fail. In addition, synthetic grafts are not suitable for use in infected areas since they may harbor bacteria and are difficult to treat with antibiotics. Preserved human vascular tissues are ideal grafts for patients with previously infected graft sites. The Company also preserves femoral veins and arteries and aortoiliac arteries for bypass orreconstruction within infected surgical areas. Wikipedia.
News Article | May 16, 2017
PALO ALTO, Calif.--(BUSINESS WIRE)--Now in its 25th year serving the medical device industry, the Wilson Sonsini Goodrich & Rosati Medical Device Conference will be held Friday, June 2, 2017 in San Francisco (www.wsgr.com/news/medicaldevice). Wilson Sonsini Goodrich & Rosati (WSGR) is a long-standing provider of legal services to technology, life sciences, medical, and growth enterprises worldwide (www.wsgr.com/WSGR/Default.aspx). In a series of topical panels presented over the course of one day, experts and presenters including industry CEOs, industry strategists, venture capitalists, investment bankers, and market analysts will discuss the challenges facing today’s Medtech start-ups and the strategies emerging in response to these challenges. Topics to be Covered in Depth During the Conference Include: * New Models for Medtech Investing * Big Medtech's Evolving Business Development Strategies * Pacific Rim Deals with U.S. Medtech * IP Value -- A Corporate and Investor Perspective * Funding Strategies for Entrepreneurs * Make America Great Again -- Insights from Washington, D.C. * University Licensing Strategies * Structuring Strategic Collaborations * Clinical Trials -- Avoiding Major Pitfalls * Making the Case for Value * IPOs and Mergers * Collaborations Between Japan and Silicon Valley * Strategic Positioning to Avoid or Minimize the Risk of Earn-out Disputes Abbott Ventures, AdvaMed, AZCA Venture Partners, Asahi Kasei Corporation, Brandon Capital Partners, CryoLife, Curation Capital, Deerfield Capital, Element Science, Emergent Medical Partners, Endeavor Vision, Enplas Corporation, ForSight Labs, iRhythm Technologies, Kaiser Permanente, KCK Group, Launchpad Digital Health, LivaNova, Longford Capital Management, M.H. Carnegie & Company, Medeon Biodesign, Medical Device Manufacturers Association (MDMA), Medpass International, Medtronic, Monterey Advisors, MVM, Nevro, Partisan Management Group, Qool Therapeutics, Redmile Group, RCT Ventures, ReThink Medical, Simplify Medical, Spirox, SRS Acquiom, Stanford University, Symap Medical, Teleflex, Terumo Corporation, The Foundry, The MedTech Strategist, TheraNova, U.S.-Japan MedTech Frontiers (USJMF), Xip, and ZOLL Medical Corporation. Among the highlights of this year's conference is the launch of WSGR’s new Partnering Hall, which will provide personalized opportunities for large Medtech consolidators and investors to meet with medical device and healthcare IT start-ups looking for investment, partnering, and acquisition opportunities. Partnering Hall is a feature of the conference web app and was created to help facilitate targeted networking and business development opportunities. Investors will have access to detailed executive summaries from start-ups attending the conference and special software that will allow interested parties to arrange one-on-one meetings. The conference will conclude with a wine tasting reception featuring wines from several California wineries. Local venture capitalists will serve as sommeliers for the event. A dinner and keynote interview will be held the evening before the conference, and will feature a conversation with Michael DeMane, chairman of Nevro, an innovative medical device company based in Redwood City, California. DeMane took Nevro public in late 2014 at a $425 million valuation, and in seven short months, he helped grow the company’s value to more than $1 billion. The dinner and interview will take place at the Sharon Heights Golf & Country Club in Menlo Park. Registration for the conference (including the wine tasting reception) is open to the public (http://www.cvent.com/d/5vqhc4/4W). Tickets to the June 1 dinner and keynote program are not included with conference registration and are available at an additional cost. For more information about the conference or the new Partnering Hall contact 650-320-4529.
CryoLife | Date: 2015-02-18
Methods are provided that include applying to a surgical field in the patient following a lymphadenectomy or other procedure in which a lymph node or lymphatic vessel is dissected, a bioresorbable and biocompatible material in an amount effective to control oozing of lymphatic fluid. The material may be a hydrophilic polysaccharide material which, in contact with tissues in the surgical field, produces a gelled matrix that adheres to and forms a mechanical barrier with tissues in the surgical field to control oozing of lymphatic fluid. The hydrophilic polysaccharide material may include a modified starch such as a cross-linked carboxymethyl polysaccharide.
CryoLife | Date: 2011-04-20
Method of making self-supporting, shaped, three-dimensional cross-linked proteinaceous biopolymeric materials. The biopolymeric materials most preferably include reinforcing media, such as biocompatible fibrous or particulate materials. In use, the preformed, shaped biopolymeric materials may be applied to tissue in need of repair and then sealed around its edges with a liquid bioadhesive. In such a manner, repaired tissue which is capable of withstanding physiological pressures may be provided.
CryoLife | Date: 2014-03-07
A method is provided for preparing a biological tissue for implantation. The method includes providing a biological tissue from a human or animal donor, treating the biological tissue with an antiviral treatment formulation, lysing the biological tissue, decellularizing the biological tissue with a decellularization treatment formulation, and decontaminating the biological tissue with an alkaline alcohol solution. The antiviral treatment formulation may include a solution of peracetic acid and an alcohol, wherein the peracetic acid is present in the antiviral treatment formulation at a concentration from about 0.03% to about 1.2% (v/v). The decellularization solution may include a solution of a polar aprotic solvent, such as dimethyl sulfoxide, benzyl alcohol and ethanol.
CryoLife | Date: 2013-01-30
A method is provided for preparing a tissue implant for implantation. The method includes harvesting a tissue material from a human or an animal donor, treating the tissue material in a nuclease-containing solution, and thereafter treating the tissue material with an alkaline alcohol solution. The nuclease-containing solution includes an antimicrobial. The alkaline alcohol solution comprises sodium hydroxide and ethanol.
CryoLife | Date: 2016-01-14
A connector for fluidly coupling proximal and distal tubular segments of a fluid conduit is provided. In one embodiment, the connector can include a connector body having an outer surface defining a first outer perimeter and an inner surface defining a lumen. The connector can also include a connecting device having an open configuration and a plurality of closed configurations. The connecting device can include first and second members configured to engage each other to secure the fluid conduit to the connector. The connecting device can also include a plurality of closed configurations for securing fluid conduits of different sizes.
CryoLife | Date: 2014-08-04
Systems and methods for a blood conduit for fluidly coupling a first vascular segment to a second vascular segment are disclosed herein. In one embodiment, a system for fluidly coupling proximal and distal tubular segments of a fluid conduit in a cardiovascular system is provided. The system may include a first engagement feature disposed on a distal end of the proximal tubular segment. The system also may include a second engagement feature disposed on a proximal end of the distal tubular segment. The first engagement feature may be configured to mate with the second engagement feature. In this manner, continuous flow may be provided between the proximal and distal tubular segments of the fluid conduit. In another embodiment, the proximal and distal tubular segments of the fluid conduit may collectively form a single unitary lumen without a connection device interposed between the segments.
CryoLife | Date: 2014-02-27
An apparatus and method are provided to treat a stenosis. A delivery device is provided that has an elongate tubular member coupled therewith. The elongate tubular member has an outside surface that is configured to prevent adherence of in vivo matter. The tubular member has a proximal end and a distal end and is reinforced along its length to maintain open lumen under a transverse load. The tubular member is placed in the vasculature such that the distal end of the elongate tubular member is disposed distal of a stenosis. The proximal end of the elongate tubular member is disposed inside the vessel, preferably at a location proximal of the stenosis. Thereafter, after a therapeutic period, the elongate tubular member is removed intact.
CryoLife | Date: 2011-02-23
A delivery tip extension communicates an adhesive material from a fluid applicator tip to a site within a patient. The delivery tip extension has an elongated shaft with a proximal end portion, a central body portion, and a tapered distal end portion. The central body portion has a length between about 5 cm and about 45 cm. A lumen is defined within and extends along the elongated shaft from a proximal opening to a distal opening. The elongated shaft is relatively more rigid along the central body portion than along the distal end portion to facilitate driving the elongated shaft through the patient with reduced trauma to the patient by the distal end portion. The lumen is sized and shaped along the proximal end portion for securely receiving the fluid applicator tip inserted through the proximal opening such that a dispensing outlet on the fluid applicator tip is in fluid communication with the lumen. The delivery tip extension is sterilized or sterilizable.
CryoLife | Date: 2014-07-15
A connector for fluidly coupling proximal and distal tubular segments of a fluid conduit is provided. In one embodiment, a system is provided for providing continuous flow of blood between two locations in a patients cardiovascular system. A first blood conduit is provided that has a distal portion and a proximal portion. The distal portion is adapted to be inserted into a blood vessel at an insertion site and to be advanced therethrough to a location spaced apart from the insertion site. The system is provided with a connector that has a distal portion adapted to be engaged with the proximal portion of the first blood conduit and a tubular body extending proximally of the distal portion. The tubular body is adapted to be inserted into and/or attached to an end of a second blood conduit, such as a vascular graft or the like.